United States Sexually Transmitted Diseases (STD) Diagnostics Market

U.S. Sexually Transmitted Diseases (STD) diagnostics market by Product Type (Devices and Reagents & Kits), Disease (HIV/AIDS (Human immunodeficiency virus infection and acquired immune deficiency syndrome), Human papillomavirus (HPV), Herpes Simplex Virus, Chlamydia & Gonorrhea, Syphilis, and Others (Human T-lymphotropic viruses (HTLV), TV, MG infections)), Test Type (Polymerase Chain Reaction (PCR), Immunoassay, and Others (Nucleic Acid Test (NAT), antigen/antibody tests, other molecular tests)), and End-User (Hospitals, Diagnostic Centers, and Others (Clinics, Commercial/Private Labs, Public Health Labs)) is expected to grow at a steady CAGR forecast till 2032 owing to the growing incidence and prevalence of sexually transmitted diseases in the U.S., rising innovations in the development of STD diagnostics devices, and surging demand of rapid point of care testing over the traditional testing.

The U.S. Sexually Transmitted Diseases (STD) diagnostics market was valued at USD 6,547.35 million in 2024, growing at a CAGR of 8.80% during the forecast period from 2025 to 2032 to reach USD 12,775.10 million by 2032. The growing incidence and prevalence of sexually transmitted diseases (STDs) in the U.S. is driving the demand for advanced diagnostic solutions to ensure timely detection and treatment. Rising innovations in the development of STD diagnostic devices, including molecular testing platforms and automated systems, are improving accuracy and efficiency, making them highly attractive to healthcare providers. Additionally, the surging demand for rapid point-of-care (POC) testing, which offers quick and convenient results compared to traditional lab-based methods, is expanding access to STD diagnostics in diverse settings. Together, these factors are fuelling the growth of the U.S. STD diagnostics market, meeting the increasing need for effective and accessible testing solutions, during the forecast period from 2025 to 2032.

U.S. Sexually Transmitted Diseases (STD) Diagnostics Market Dynamics:

According to the data and stats provided by the U.S. Department of Health & Human Services (2024), it was stated that approximately 1.2 million people in the U.S. have HIV, and about 13 percent of them don’t know it and need testing. Additionally, in 2022, an estimated 31,800 people acquired HIV in the U.S. Thus, due to the increase in the number of cases, routine HIV testing has become a cornerstone of public health initiatives, driven by guidelines emphasizing early and frequent screening, especially for high-risk populations. The introduction of advanced diagnostic technologies, such as rapid antigen/antibody combination tests, point-of-care devices, and nucleic acid testing, has significantly improved the accuracy and speed of HIV detection, further fuelling market growth.

Additionally, advancements in diagnostic technologies have facilitated the development of point-of-care testing devices for STDs. These devices enable rapid testing and immediate treatment decisions, particularly in resource-limited settings or remote areas where access to laboratory facilities is limited. For instance in February 2024, Visby Medical received U.S.D 1.8 million from CARB-X to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea.

Additionally, as per the Centers for Disease Control and Prevention (2022), preliminary data it was estimated that 2.5 million cases of sexually transmitted diseases such as chlamydia, gonorrhea, and syphilis were reported in the United States in 2022. Thus, the number of rising STD cases in the U.S. will create a need for the diagnosis and treatment of sexually transmitted disorders, thereby propelling the overall market growth of the sexually transmitted disease diagnostics market in the U.S. during the forecasted period.

Thus, the factors mentioned above are expected to boost the overall market of the U.S. Sexually Transmitted Diseases (STD) diagnostics market during the forecast period from 2025 to 2032.

However, stringent regulatory approvals for devices and social stigma associated with patients visiting physicians for STD diagnosis and treatment may hinder the future market of the U.S. Sexually Transmitted Diseases (STD) diagnostics market during the forecasted period.

U.S. Sexually Transmitted Diseases (STD) Diagnostics Market Segment Analysis:

U.S. Sexually Transmitted Diseases (STD) diagnostics market by Product Type (Devices and Reagents & Kits), Disease (HIV/AIDS (Human immunodeficiency virus infection and acquired immune deficiency syndrome), Human papillomavirus (HPV), Herpes Simplex Virus, Chlamydia & Gonorrhea, Syphilis, and Others (Human T-lymphotropic viruses (HTLV), TV, MG infections)), Test Type (Polymerase Chain Reaction (PCR), Immunoassay, and Others (Nucleic Acid Test (NAT), antigen/antibody tests, other molecular tests)), and End-User (Hospitals, Diagnostic Centers, and Others (Clinics, Commercial/Private Labs, Public Health Labs))

The reagents & kits category in the U.S. Sexually Transmitted Diseases (STD) diagnostics market is estimated to dominate the market with a market share of 71.32% in 2024. This can be attributed to the varied applications and the specificity associated with reagents and kits in the sexually transmitted disease diagnostics market, responsible for the increased demand for reagents and kits during the given forecast period. For the treatment of sexually transmitted disease conditions, proper diagnosis can only be ensured using high-quality reagents and kits. Modern technological advancements have made it easier to produce countless kits and reagents for sexual disease diagnosis. Moreover, the involvement of World Health Organization in facilitating and ensuring the quality standards of kits produced locally and imported both are also expected to drive the market growth for reagents and kits.  The guidelines by the WHO cover legal, technical, and administrative elements and offer a solid foundation for guaranteeing the quality of diagnostic reagents and kits for STD diagnostics. 

Additionally, the ease of use and accessibility of these kits, including at-home testing solutions, have contributed to greater adoption, particularly among individuals seeking private and discreet testing. Reagents and kits also support the growing trend of point-of-care (POC) testing, which allows for immediate results and treatment decisions. As a result, the availability of advanced reagents and kits is driving the market by improving testing capabilities, reducing testing time, and expanding access to STD diagnostics, thereby contributing to earlier detection and better management of sexually transmitted infections (STIs). In addition, in November 2023, LetsGetChecked was given marketing authorization by the US Food and Drug Administration for its Simple 2 Test. This is the first diagnostic test to receive marketing authorization for gonorrhea and chlamydia that uses at-home sample collection. It's the first test for any STD other than HIV that the FDA had approved, allowing sample collection to take place at home. The FDA also verified home collection kits with the intended test and reviewed LetsGetChecked data showing consumers could properly use the kit, comprehend the results in general, and take any necessary follow-up steps. 

Hence, owing to all the aforementioned factors, the market will experience an increased demand for reagents and kits in sexually transmitted disease diagnostics, thus driving the U.S sexually transmitted disease diagnostics market during the forecast period.

U.S. Sexually Transmitted Diseases (STD) Diagnostics Market Key Players:

Some of the key market players operating in the U.S. Sexually Transmitted Diseases (STD) diagnostics market include Abbott, DiaSorin S.p.A., Hologic, Inc., Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Institut Mérieux, Thermo Fisher Scientific Inc., BD, and others.

Recent Developmental Activities in the U.S. Sexually Transmitted Diseases (STD) Diagnostics Market:

• In November 2023, the U.S. FDA granted marketing authorization to LetsGetChecked for the Simple 2 Test for chlamydia and gonorrhea. The Simple 2 Test is accessible for purchase over-the-counter (OTC) and is designed for adult patients aged 18 years and above. It marked the first FDA-authorized test allowing at-home sample collection for any sexually transmitted disease besides HIV. 
• In May 2022, Abbott announced that it had received FDA clearance for its Alinity™ m STI Assay. The test simultaneously detects and differentiates four common sexually transmitted infections (STIs). STIs, when left untreated, can lead to severe health complications, including increased risk of getting certain cancers and infertility.

Key Takeaways From the U.S. Sexually Transmitted Diseases (STD) Diagnostics Market Report Study

• Market size analysis for current U.S. Sexually Transmitted Diseases (STD) diagnostics market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the U.S. Sexually Transmitted Diseases (STD) diagnostics market.
• Various opportunities available for the other competitors in the U.S. Sexually Transmitted Diseases (STD) diagnostics market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current U.S. Sexually Transmitted Diseases (STD) diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for U.S. Sexually Transmitted Diseases (STD) diagnostics market growth in the coming future?

Target Audience Who Can be Benefited from this U.S. Sexually Transmitted Diseases (STD) Diagnostics Market Report Study

• U.S. Sexually Transmitted Diseases (STD) diagnostics market product providers
• Research organizations and consulting companies 
• U.S. Sexually Transmitted Diseases (STD) diagnostics market-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in the U.S. Sexually Transmitted Diseases (STD) diagnostics market 
• Various end-users who want to know more about the U.S. Sexually Transmitted Diseases (STD) diagnostics market and the latest technological developments in the U.S. Sexually Transmitted Diseases (STD) diagnostics market.

Frequently Asked Questions for the U.S. Sexually Transmitted Diseases (STD) Diagnostics Market:

1. What are Sexually Transmitted Diseases (STD) diagnostics?

• Sexually Transmitted Diseases (STD) diagnostics refer to the medical tests and procedures used to detect and identify infections transmitted through sexual contact. These diagnostics include laboratory-based methods, rapid point-of-care tests, and molecular techniques, enabling the accurate detection of pathogens like bacteria, viruses, and parasites that cause STDs such as chlamydia, gonorrhea, syphilis, and HIV.

2. What is the market for the U.S. Sexually Transmitted Diseases (STD) diagnostics?

• The U.S. Sexually Transmitted Diseases (STD) diagnostics market was valued at USD 6,547.35 million in 2024, growing at a CAGR of 8.80% during the forecast period from 2025 to 2032 to reach USD 12,775.10 million by 2032. 

3. What are the drivers for the U.S. Sexually Transmitted Diseases (STD) diagnostics market?

• The growing incidence and prevalence of sexually transmitted diseases (STDs) in the U.S. is driving the demand for advanced diagnostic solutions to ensure timely detection and treatment. Rising innovations in the development of STD diagnostic devices, including molecular testing platforms and automated systems, are improving accuracy and efficiency, making them highly attractive to healthcare providers. Additionally, the surging demand for rapid point-of-care (POC) testing, which offers quick and convenient results compared to traditional lab-based methods, is expanding access to STD diagnostics in diverse settings. Together, these factors are fuelling the growth of the U.S. STD diagnostics market, meeting the increasing need for effective and accessible testing solutions, during the forecast period from 2025 to 2032.

4. Who are the key players operating in the U.S. Sexually Transmitted Diseases (STD) diagnostics market?

• Some of the key market players operating in the U.S. Sexually Transmitted Diseases (STD) diagnostics market are Abbott, DiaSorin S.p.A., Hologic, Inc., Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Institut Mérieux, Thermo Fisher Scientific Inc., BD, and others.